Current process and future path for health economic assessment of pharmaceuticals in France.
The Social Security Funding Law for 2012 introduced the Economic and Public Health Assessment Committee (Commission Evaluation Economique et de Santé Publique, or CEESP) in the Social Security Code as a specialised committee affiliated with the Haute Autorité de Santé in charge of providing recommendations and health economic opinions. This article provides an in-depth description of the CEESP's structure and working methods, and analyses the impact of health economic assessment on market access of drugs in France. It also points out the areas of uncertainty and the conflicting rules following the introduction of the health economic assessment in France. The authors also provide their personal opinion on the likely future of health economic assessment of drugs in France, including the possible merge of the CEESP and the Transparency Committee, the implementation of a French threshold, and the extension of health economic assessment to a larger number of products.
Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Université de la Méditerranée, Marseille Cedex, France.
Mondher
M
Toumi
Creativ-Ceutical, Paris, France.
Cécile
C
Rémuzat
Evidenz, Tunis, Tunisia.
Emna
E
El Hammi
Creativ-Ceutical, Paris, France.
Aurélie
A
Millier
Creativ-Ceutical, Paris, France.
Samuel
S
Aballéa
INSERM U955 and Université Paris Est (UPEC), UMR U955, Faculté de médecine, F-94010, Créteil, France; Centre Hospitalier Intercommunal, DHU-ATVB, Département de Pneumologie et Pathologie Professionnelle, F-94000, Créteil, France.
Christos
C
Chouaid
INSERM Unit U669 (Public Health and Mental Health), University Paris-Sud, Maison de Solenn, Paris, France.
Bruno
B
Falissard
CEESP; France; HAS; cost-effectiveness; health economic assessment; market access